Literature DB >> 32063487

What is the role of medical therapy in adrenal-dependent Cushing's syndrome?

Leah T Braun1, Martin Reincke2.   

Abstract

Medical therapy to control hypercortisolism in adrenal Cushing's syndrome is currently not the first-line therapy. However, in many clinical scenarios like pre-surgical treatment, in patients who are not suitable candidates for surgery or in patients with bilateral hyperplasia, medical therapy can be important representing the only viable treatment option. Adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers have been used for many years: metyrapone, ketoconazole and mifepristone are in current use and effective. Mitotane can be used as well but is considered second-line therapy because of its high toxicity. Etomidate has a special position as emergency medication in severe hypercortisolism. New drugs are tested in prospective trials (levoketoconazole, osilidrostat and relacorilant) and might become effective alternatives to common drugs. Oher drugs - adrenal steroidogenesis inhibitors as well as glucocorticoid receptor antagonists - are currently tested in vitro.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  adrenal steroidogenesis inhibitors; glucocorticoid receptor blockers; hypercortisolism; ketoconazole; metyrapone; therapy

Mesh:

Substances:

Year:  2020        PMID: 32063487     DOI: 10.1016/j.beem.2020.101376

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  2 in total

1.  Levoketoconazole.

Authors:  Nicole K McCartney; Danial E Baker
Journal:  Hosp Pharm       Date:  2022-08-02

2.  The effects of selected inhibitors on human fetal adrenal steroidogenesis differs under basal and ACTH-stimulated conditions.

Authors:  Cecilie Melau; Malene Lundgaard Riis; John E Nielsen; Signe Perlman; Lene Lundvall; Lea Langhoff Thuesen; Kristine Juul Hare; Mette Schou Hammerum; Rod T Mitchell; Hanne Frederiksen; Anders Juul; Anne Jørgensen
Journal:  BMC Med       Date:  2021-09-08       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.